| 23 |
Zhou C, Guang Y, Luo Y, et al. MAGNET AECOPD registry investigators. superior predictive value of d-dimer to the padua prediction score for venous thromboembolism in inpatients with AECOPD: a multicenter cohort study[J]. Int J Chron Obstruct Pulmon Dis, 2022 , 17: 2711-2722.
|
| 24 |
宗海娟，张蓉蓉，卢坤琴. 慢性阻塞性肺疾病继发肺栓塞的危险因素分析[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(1): 58-60.
|
| 25 |
王东旭，陈旭华. 心房颤动合并慢性阻塞性肺疾病的研究进展[J]. 解放军医学杂志，2023, 48(3): 355-359.
|
| 26 |
Chen X, Huang J, Liu J, et al. Derivation and external validation of a risk assessment model of venous thromboembolism in hospitalized chinese patients[J]. Clin Appl Thromb Hemost, 2023, 29: 10760296221151164.
|
| 27 |
Bertoletti L, Couturaud F, Sanchez O, et al. Pulmonary embolism and chronic obstructive pulmonary disease[J]. Semin Thromb Hemost, 2022, 15.
|
| 28 |
Bartholomew JR. Update on the management of venous thromboembolism[J]. Cleve Clin J Med, 2017, 84(12 Suppl 3): 39-46.
|
| 29 |
鲁乔丹，王 磊，邓海波，等. 抗凝药物用药满意度评估工具的研究进展[J]. 中华现代护理杂志，2023, 29(17): 2371-2375.
|
| 30 |
Derbalah A, Duffull S, Newall F, et al. Revisiting the pharmacology of unfractionated heparin[J]. Clin Pharmacokinet, 2019, 58(8): 1015-1028.
|
| 31 |
Huang X, Han S, Liu X, et al. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis[J]. Exp Ther Med, 2020, 19(2): 913-922.
|
| 32 |
罗振军，罗 胜，何小宇. 低分子肝素抗凝治疗在COPD急性加重并发呼吸衰竭疑诊急性肺栓塞中的应用价值[J]. 海南医学，2021, 32(2): 153-156.
|
| 33 |
Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis[J]. Thromb Res, 2019, 173: 158-163.
|
| 34 |
王振兴，徐冷楠，付沛颉，等. 抗Xa因子活性检测在血液透析患者低分子肝素抗凝中的应用进展[J]. 中国血液净化，2022, 21(5): 365-368.
|
| 35 |
Segon YS, Summey RD, Slawski B, et al. Surgical venous thromboembolism prophylaxis: clinical practice update[J]. Hosp Pract (1995), 2020, 48(5): 248-257.
|
| 36 |
邓明影，张 蕾，冯晓俊，等. 临床药师参与1例下肢静脉血栓伴肺动脉血栓栓塞症患者华法林个体化抗凝治疗方案的病例分析[J]. 中国药房，2019, 30(6): 836-839.
|
| 37 |
Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the american college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2021, 77(5): 629-658.
|
| 38 |
Smythe MA, Parker D, Garwood CL, et al. Timing of initiation of oral anticoagulation after acute ischemic stroke in patients with atrial fibrillation[J]. Pharmacotherapy, 2020, 40(1): 55-71.
|
| 39 |
Foerster KI, Hermann S, Mikus G, et al. Drug-drug interactions with direct oral anticoagulants[J]. Clin Pharmacokinet, 2020, 59(8): 967-980.
|
| 40 |
Khider L, Gendron N, Mauge L. Inherited thrombophilia in the era of direct oral anticoagulants[J]. Int J Mol Sci, 2022, 23(3): 1821.
|
| 41 |
Margetic S, Goreta SŠ，Celap I, et al. Direct oral anticoagulants (DOACs): From the laboratory point of view[J]. Acta Pharm, 2022, 72(4): 459-482.
|
| 42 |
Ahrens I, Bode C. New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors[J]. Curr Drug Discov Technol, 2012, 9(2): 129-36.
|
| 43 |
蔡 亮，丁 勇，周 旻，等. 利伐沙班与传统抗凝药物在80岁以上静脉血栓栓塞症患者中的有效性与安全性对比[J]. 中国临床医学，2019, 26(2): 272-276.
|
| 44 |
郑绪雅，张 琳，张俊峰. 非瓣膜性心房颤动患者ABCB1和CES1基因多态性对达比加群酯抗凝疗效的影响[J]. 临床检验杂志，2021, 39(12): 903-908.
|
| 45 |
李佳乐，赵 莉. 达比加群酯抗凝治疗合理性和安全性评价[J]. 中国医院药学杂志，2019, 39(21): 2176-2180.
|
| 46 |
姚 莉，赵生俊，唐晓丽. 静脉血栓栓塞症患者口服抗凝药物导致出血的多因素分析研究[J]. 重庆医学，2022, 51(22): 3895-3898, 3902.
|
| 47 |
于 彦，郭维琴. 郭维琴教授中医药治疗肺栓塞的经验总结[J]. 世界中西医结合杂志，2021, 16(6): 1017-1020, 1025.
|
| 48 |
陈东海，马玉莹，徐泽林，等. 肺血栓栓塞症"瘀阻痰结"的中医病机及治疗[J]. 中医药导报，2022, 28(9): 93-96.
|
| 49 |
Meitei SP, Tale S, Negi AK, et al. Prevalence and characteristics of venous thromboembolism in severe exacerbation of chronic obstructive pulmonary disease in a tertiary care hospital in India[J]. Monaldi Arch Chest Dis, 2021, 91(4).
|
| 50 |
Alparslan Bekir S, Tuncay E, Gungor S, et al. Can red blood cell distribution width (RDW) level predict the severity of acute exacerbation of chronic obstructive pulmonary disease (AECOPD)？[J]. Int J Clin Pract, 2021, 75(11): e14730.
|
| 51 |
Petris OR, Cojocaru E, Fildan AP, et al. COPD and anticoagulation therapy: time for a new approach？[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 3429-3436.
|
| 52 |
Zhang X, Wu Y, Lv C, et al. Efficacy and safety of oral anticoagulants in elderly patients with stable coronary artery disease and atrial fibrillation[J]. Thromb J, 2022, 20(1): 66.
|
| 1 |
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
| 2 |
陈国华，万 秋，何 婷，等. 慢性阻塞性肺疾病合并肺血栓栓塞症的研究进展[J]. 检验医学与临床，2022, 19(9): 1286-1289.
|
| 3 |
Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with Acutely worsening respiratory symptoms[J]. JAMA, 2021, 325(1): 59-68.
|
| 4 |
Jiménez D, Agustí A, Tabernero E, et al. Effect of a pulmonary embolism diagnostic strategy on clinical outcomes in patients hospitalized for COPD exacerbation: a randomized clinical trial[J]. JAMA, 2021, 326(13): 1277-1285.
|
| 5 |
Polverino F, Kheradmand F. COVID-19, COPD, and AECOPD: immunological, epidemiological, and clinical aspects[J]. Front Med (Lausanne), 2021, 7: 627278.
|
| 6 |
Hoult G, Gillespie D, Wilkinson TMA, et al. Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis[J]. BMC Pulm Med, 2022, 22(1): 194.
|
| 7 |
Crisafulli E, Barbeta E, Ielpo A, et al. Management of severe acute exacerbations of COPD: an updated narrative review[J]. Multidiscip Respir Med, 2018, 13: 36.
|
| 8 |
李传苍，周雅冰，张梦鸽，等. 2010-2020年中国居民慢性阻塞性肺疾病死亡趋势分析[J].郑州大学学报(医学版), 2023, 58(2): 269-273.
|
| 9 |
Xu J, Wang X, Li Z, et al. AECOPD research in the past ten years: a bibliographic analysis based on Web of Science[J]. Ann Palliat Med, 2021, 10(10): 10401-10413.
|
| 10 |
Piazza G, Goldhaber SZ, Kroll A, et al. Venous thromboembolism in patients with chronic obstructive pulmonary disease[J]. Am J Med, 2012, 125(10): 1010-1018.
|
| 11 |
Dong W, Zhu Y, Du Y, et al. Association between features of COPD and risk of venous thromboembolism[J]. Clin Respir J, 2019, 13(8): 499-504.
|
| 12 |
Ambrosetti M, Ageno W, Spanevello A, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD[J]. Thromb Res, 2003, 112(4): 203-207.
|
| 13 |
陈艳蓉，石 赟，王 珊，等. 老年慢性阻塞性肺疾病急性加重期患者血清CTRP-4、CTRP-6、CTRP-9与肺功能和炎症因子的相关性分析[J]. 现代生物医学进展，2023, 23(10): 1857-1861.
|
| 14 |
李 佳，陈小兰，潘 磊. 老年慢性阻塞性肺疾病急性加重病人发生静脉血栓栓塞症的临床特征和危险因素分析[J]. 实用老年医学，2022, 36(4): 374-377.
|
| 15 |
尹宁宁，王志娟，张海霞. 慢性阻塞性肺疾病患者并发心血管疾病危险因素及预测模型建立[J]. 川北医学院学报，2023, 38(5): 608-612.
|
| 16 |
魏港吉，陈晓芳，陈小芳，等. 吸烟对四川省30岁及以上居民慢性阻塞性肺疾病发病风险影响的前瞻性研究[J]. 中华流行病学杂志，2023, 44(5): 778-785.
|
| 17 |
张 童，魏丽娟，李冠颖，等. 慢性阻塞性肺疾病急性加重患者3年内再住院影响因素分析[J]. 成都医学院学报，2023, 18(2): 168-171.
|
| 18 |
蒋国云，杨德兴，赵 琨，等. ICU患者下肢深静脉血栓形成的危险因素分析[J]. 昆明医科大学学报，2020, 41(10): 40-49.
|
| 19 |
冷 婷，任 惠，周雨婷. 老年慢性阻塞性肺疾病合并肺栓塞患者的临床特征及其危险因素分析[J/CD]. 中国医学前沿杂志(电子版), 2019, 11(9): 73-76.
|
| 20 |
Keller K, Wöllner J, Schmitt VH, et al. Risk factors for pulmonary embolism in patients with paralysis and deep venous thrombosis[J]. J Clin Med, 2021 , 10(22): 5412.
|
| 21 |
李 莉，薛 莲，伍梦寒. 糖尿病肾病患者凝血功能血浆血红蛋白和D-D水平及其与血液透析动静脉内瘘血栓形成的关系研究[J]. 河北医学，2023, 29(1): 107-112.
|
| 22 |
白克林. 血清淀粉样蛋白A联合D-二聚体对老年慢性阻塞性肺疾病急性加重期患者近期预后的预测价值[J]. 临床与病理杂志，2023, 43(3): 477-483.
|